Bayer AG’s Observational Study on Vericiguat: Real-World Insights into Heart Failure Treatment

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG is conducting an observational study titled Retrospective, Non-interventional Database Study for the Evaluation of Real-world Drug Use Patterns, Clinical Characteristics and Clinical Outcomes in Patients Initiated on Vericiguat in India. The study aims to assess the safety and effectiveness of Vericiguat in Indian patients with chronic heart failure with reduced ejection fraction (HFrEF) and worsening heart failure. This study is significant as it seeks to provide real-world data on Vericiguat’s impact, which could enhance treatment strategies for heart failure.

Intervention/Treatment: The study focuses on Vericiguat, a drug that enhances the activity of the enzyme soluble guanylate cyclase (sGC), helping relax blood vessels and improve heart function. Vericiguat is already approved for use in patients with worsening chronic HFrEF in India.

Study Design: This is a retrospective, observational cohort study. It involves analyzing existing data from patients who began Vericiguat treatment between September 2022 and August 2023. The study does not involve any new interventions or patient visits, as it relies on data from routine care.

Study Timeline: The study is set to start on August 1, 2025, with primary completion expected by February 2024. The last update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipated data availability.

Market Implications: This study could influence Bayer AG’s stock performance by providing valuable insights into Vericiguat’s real-world effectiveness, potentially boosting investor confidence. As heart failure treatments are a competitive market, positive outcomes could position Bayer favorably against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.